131 filings
Page 2 of 7
8-K
t72030r s6xjndokd
27 Oct 22
Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference
8:34am
8-K
qkmg7 n63lytqf32
18 Oct 22
Other Events
8:41am
8-K
6konqbw1iu
14 Oct 22
Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split
8:55am
8-K
jo95wm y3ef
12 Aug 22
Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
6:16pm
8-K
j5s7vf
3 Aug 22
Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement
4:27pm
8-K
vqvdklnnjr 64o
17 Jun 22
Submission of Matters to a Vote of Security Holders
5:03pm
8-K
f3ngg
12 May 22
Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results
4:14pm
8-K
t7sryf
26 Apr 22
Other Events
5:14pm
8-K
6ruhw9157q5i
22 Apr 22
Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering
8:47am
8-K
s5xi0gp6g
1 Apr 22
Amendments to Articles of Incorporation or Bylaws
4:01pm
8-K
e1sryg m1awj
10 Mar 22
Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results
4:12pm
8-K
gfcu8jv47 0c
13 Jan 22
Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC
4:05pm
8-K
xpe7vs7p
19 Nov 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:17pm
8-K
3bwyigjo43 cz3f
16 Sep 21
Other Events
4:26pm
8-K
8p8 012w78zb
20 Aug 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
vekz70kb
5 Aug 21
Salarius Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress
4:13pm
8-K
5j0djq 53kf
2 Jul 21
Other Events
5:07pm
8-K
5rttlmwsg
1 Jul 21
Other Events
5:18pm
8-K
al3beeprifp68irs zm
16 Jun 21
Submission of Matters to a Vote of Security Holders
4:27pm
8-K
qzq9i7nhngim40k44
20 May 21
Other Events
7:57am